HNSCC Clinical Trials

92 clinical trials for HNSCC across international registries, including 36 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• First in Human Study of TUB-030 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer — RECRUITING · PHASE1
• Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer — RECRUITING · PHASE1
• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer — RECRUITING · PHASE1
• Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma — RECRUITING
• Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) — RECRUITING · PHASE1
• A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial) — RECRUITING · PHASE1
• A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC — RECRUITING · PHASE1
• Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies — RECRUITING · PHASE2
• A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors — RECRUITING · PHASE1
• Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas. — RECRUITING · PHASE3
• A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors — RECRUITING · PHASE1
• High-Resolution PET-CT Imaging for Surgical Margin Visualization — RECRUITING · NA
• Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC — RECRUITING · PHASE1
• Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors — RECRUITING · NA
• DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors — RECRUITING · PHASE1
• A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors — RECRUITING · PHASE1
• Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer — RECRUITING · PHASE1
• A Study of YL202 in Selected Patients With Advanced Solid Tumors — RECRUITING · PHASE2
• A Study of GV20-0251 in Advanced or Refractory Solid Tumors — RECRUITING · PHASE1
• Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors — RECRUITING · PHASE1
• A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy — RECRUITING
• A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression — RECRUITING · PHASE1
• Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC — RECRUITING · PHASE2
• Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy — RECRUITING
• Using a 3D Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With HNSCC Cancer — RECRUITING
• Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer — RECRUITING · PHASE1
• A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus — RECRUITING · PHASE1
• Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma — RECRUITING · PHASE1
• A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors — RECRUITING · PHASE1
• Artificial Intelligence in Functional Imaging for Individualized Treatment of Head and Neck Squamous Cell Carcinoma Patients — RECRUITING
• 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC — RECRUITING · PHASE2
• PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy — RECRUITING · PHASE3
• COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies — COMPLETED · PHASE1
• Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC) — NOT_YET_RECRUITING · PHASE1
• A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants — NOT_YET_RECRUITING · PHASE2
• Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC — ACTIVE_NOT_RECRUITING · PHASE1
• Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) — COMPLETED · PHASE1
• Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial) — TERMINATED · PHASE2
• Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC — COMPLETED · PHASE2
• Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial — NOT_YET_RECRUITING · PHASE2
• Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC — COMPLETED · PHASE1
• Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma — COMPLETED · PHASE2

Refine this search